| Ytd | 20.95% | |
| 1y | 775.16% |
| Open | 28.93 | Prev Close | 29.00 | Low | 27.80 | High | 28.93 | Mkt Cap | 1.72B |
| Vol | 30.01K | Avg Vol | 565.97K | EPS | -0.26 | P/E | N/A | Forward P/E | -13.54 |
| Beta | 1.47 | Short Ratio | 11.63 | Inst. Own | 105.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 29.04 | 200-d Avg | 25.96 | 1yr Est | 44.67 |
DMRA News
Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR)
Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the anal
Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant c
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio
Wedbush analyst David Nierengarten maintains Damora Therapeutics (NASDAQ:DMRA) with a Outperform
Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings p
Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check a
Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Damora Therapeutics (NASDAQ:DMRA) w
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ:
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Damora Therapeutics (NAS
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bio
Wedbush analyst David Nierengarten initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a
Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They h
On track to make the first regulatory submission for DMR-001 in mid-2026 enabling the initiation of
Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.62) per share which missed the an
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR
https://www.sec.gov/ix?doc=/Archives/edgar/data/1800315/000119312526203913/dmra-20260428.htm
BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biot
RBC Capital analyst Brian Abrahams initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a
Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an ave
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's fi
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DA
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a bi
Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) have earned an ave
Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzing
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Damora Therapeutics (NASDAQ:
-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datase
